A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls.
(2015) In Pediatric Infectious Disease Journal 34(9). p.992-998- Abstract
- A 9-valent human papillomavirus (9vHPV) vaccine has been developedto prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV [qHPV] vaccine), as well as 5additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine vs. the qHPV vaccine in 9-15-year-old girls.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7484626
- author
- Vesikari, Timo ; Brodszki, Nicholas LU ; van Damme, Pierre ; Diez-Domingo, Javier ; Icardi, Giancarlo ; Kjeld Petersen, Lone ; Tran, Clément ; Thomas, Stéphane ; Luxembourg, Alain and Baudin, Martine
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Pediatric Infectious Disease Journal
- volume
- 34
- issue
- 9
- pages
- 992 - 998
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- pmid:26090572
- wos:000360398600016
- scopus:84940027111
- pmid:26090572
- ISSN
- 1532-0987
- DOI
- 10.1097/INF.0000000000000773
- language
- English
- LU publication?
- yes
- id
- 4385140e-f7eb-40d8-841b-4e8bc14cdafb (old id 7484626)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26090572?dopt=Abstract
- date added to LUP
- 2016-04-01 10:30:52
- date last changed
- 2022-04-27 22:47:37
@article{4385140e-f7eb-40d8-841b-4e8bc14cdafb, abstract = {{A 9-valent human papillomavirus (9vHPV) vaccine has been developedto prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV [qHPV] vaccine), as well as 5additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine vs. the qHPV vaccine in 9-15-year-old girls.}}, author = {{Vesikari, Timo and Brodszki, Nicholas and van Damme, Pierre and Diez-Domingo, Javier and Icardi, Giancarlo and Kjeld Petersen, Lone and Tran, Clément and Thomas, Stéphane and Luxembourg, Alain and Baudin, Martine}}, issn = {{1532-0987}}, language = {{eng}}, number = {{9}}, pages = {{992--998}}, publisher = {{Lippincott Williams & Wilkins}}, series = {{Pediatric Infectious Disease Journal}}, title = {{A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls.}}, url = {{http://dx.doi.org/10.1097/INF.0000000000000773}}, doi = {{10.1097/INF.0000000000000773}}, volume = {{34}}, year = {{2015}}, }